Aptose Biosciences Inc. (NASDAQ:APTO) has been given a consensus rating of “Buy” by the six ratings firms that are presently covering the company. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $12.67.

A number of equities analysts have recently weighed in on APTO shares. RBC Capital Markets reiterated an “outperform” rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. Royal Bank Of Canada reiterated an “outperform” rating and set a $23.00 price target on shares of Aptose Biosciences in a report on Saturday, June 25th. Roth Capital reiterated a “buy” rating and set a $8.00 price target on shares of Aptose Biosciences in a report on Friday. Zacks Investment Research upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 11th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $7.00 price target on shares of Aptose Biosciences in a report on Saturday.

A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned 0.43% of Aptose Biosciences as of its most recent filing with the SEC. 19.47% of the stock is currently owned by institutional investors.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/aptose-biosciences-inc-apto-given-consensus-rating-of-buy-by-analysts.html

Shares of Aptose Biosciences (NASDAQ:APTO) traded down 7.3409% during midday trading on Tuesday, hitting $2.0385. The stock had a trading volume of 67,934 shares. Aptose Biosciences has a one year low of $1.92 and a one year high of $6.40. The firm has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.46. The stock’s market cap is $26.28 million.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

5 Day Chart for NASDAQ:APTO

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.